A multicenter study on the efficacy and influencing factors of Insect Compound Particle in the treatment of MMR related stage III colorectal cancer

Phase 1

• Conditions: colorectal cancer

• Registration Number: ITMCTR2000003945
• Lead Sponsor: Shanghai Municipal Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) According to the above diagnostic criteria, the patient was diagnosed as stage III colorectal cancer;
(2) Patients who agreed to undergo radical surgery and were confirmed by histopathology as TN1-2M0 and MMR detected by immunohistochemistry;
(3) Aged >=18 years;
(4) Patients with expected survival time >=6 months; ECoG <=2;
(5) The patient agreed to be followed up;
(6) The follow-up and clinical data will be complete;
(7) Patients voluntarily sign informed consent.

Exclusion Criteria

(1) Complicated with other primary malignant tumor;
(2) Complicated with serious heart, brain, liver, kidney disease, electrolyte abnormality or mental illness;
(3) Patients who are allergic to the drugs used in this study or their ingredients;
(4) Pregnancy, lactation or planned pregnancy;
(5) There are serious or uncontrollable infections;
(6) Those who took other traditional Chinese medicine or participated in other clinical trials in recent 2 weeks.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
DFS;

Secondary Outcome Measures

Name	Time	Method
Quality of life scale;OS;TCM symptom score scale;Safety-related physical and chemical indicators;